This document discusses inflammatory multfocal chorioretinopathies, which are a heterogeneous group of diseases that affect the outer retina, retinal pigment epithelium, choroid, or a combination. It summarizes the key characteristics, ocular manifestations, diagnosis, treatment, and outcomes of several specific conditions that fall under this category, including Birdshot chorioretinopathy, Acute posterior multifocal placoid pigment epitheliopathy, Serpiginous choroiditis, Multiple evanescent white dot syndrome, and Acute zonal occult outer retinopathy.
Great talk about uveitis anterior uveitis and posterior uveitis for those who may have missed it or are not members of American Academy of Ophthalmology Meeting. Kudos to Dr. Lowder
www.ophthalclass.blogspot.com has the complete class and MCQs on uveitis for undergraduate medical students. Class 5 in the series of classes on uveitis deals with the common causes of panuveitis and briefly discusses their management. The clinical feature of each of the disease entities is explained with the help of case studies.
This is appt presentation done by me and my colleagues zakaria Abul-Nasser and Sara Hassan ( agroup of medical undergarduates , school of Medicine, Ain-shams university , Cairo , Egypt ) ...
This work was presented at the end of our Ophthalmolgy clinical round ..
I Hope every one to get the best out of the presentaion ..Any commentaries are even more appreciated :)
Great talk about uveitis anterior uveitis and posterior uveitis for those who may have missed it or are not members of American Academy of Ophthalmology Meeting. Kudos to Dr. Lowder
www.ophthalclass.blogspot.com has the complete class and MCQs on uveitis for undergraduate medical students. Class 5 in the series of classes on uveitis deals with the common causes of panuveitis and briefly discusses their management. The clinical feature of each of the disease entities is explained with the help of case studies.
This is appt presentation done by me and my colleagues zakaria Abul-Nasser and Sara Hassan ( agroup of medical undergarduates , school of Medicine, Ain-shams university , Cairo , Egypt ) ...
This work was presented at the end of our Ophthalmolgy clinical round ..
I Hope every one to get the best out of the presentaion ..Any commentaries are even more appreciated :)
www.ophthalclass.blogspot.com has the complete post.
In Part1 the topics discussed are the causes of anterior, intermediate, posterior and panuveitis. There is also a section on the associated features like history, demographics and examination findings that help to narrow down the differential diagnosis.
www.ophthalclass.blogspot.com has the complete post.
In Part1 the topics discussed are the causes of anterior, intermediate, posterior and panuveitis. There is also a section on the associated features like history, demographics and examination findings that help to narrow down the differential diagnosis.
by Cono Grasso, MD
Jamaica Hospital Medical Center
Presented at the S.L.E. Lupus Foundation's "Get into the Loop!" New York City Lupus Education Series on October 6, 2010.
Heard of people being unable to see other people's faces if not fr failure of recognition of people's faces (prosapagnosia)...then they need to get their retina in particular macula checked! And a bunch of other macular disorders are enlisted nd elaborated in the presentation
The presentation was made under the wise guidance of my professor DR.(prof) P. Rawat (MGMMC & M.Y. HOSPITAL, INDORE).It covers the essential aspects of optic neuritis & optic atrophy.
Comprehensive review of Ophthalmic Manifestations of Systemic Disorders for undergraduate medical students and general practionaers. Lecture was taken by Associate Professor Dr. Zia ul Mazhry at Central Park Medical College Lahore Pakistan.
Pachychoroid spectrum of disease now also include central serous chorioretinopathy. The presentation include history, pathogenesis, clinical features, diffrential and treatment of CSCR
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
CDSCO and Phamacovigilance {Regulatory body in India}
Posterior uveitis of unknown cause white spot syndromes
1. Bipin Bista
2nd Year Resident
Department of Ophthalmology
National medical College
& Teaching Hospital
2. A heterogeneous group of diseases that affect the outer
retina, retinal pigment epithelium(RPE),choroid or a
combination of these anatomic sites
The lesions are typically multifocal in nature
The may be present in one or both eyes
3. When bilateral they may be asymmetric
The white spots themselves may be a variable
finding.
For this reason, the name Inflammatory
Multifocal Chorioretinopathies may be more
appropriate
5. EPIDEMIOLOGY AND PATHOGENESIS
Primary lesions of the disease are in the choroid
Affects usually women between 3rd and 6th decades of
life
90% of the patient having BCR possess human
lymphocyte antigen A*29 (HLA-A*29)
6. OCULAR
MANIFSTATIONS
Blurred
vision,floaters,central and
peripheral photopsias and
later nyctalopia
Lesions are scattered around
the optic disk
Radiate to the equator in a
‘shot gun’ pattern
Creamy lesions are small
and less than 1 disk
diameter in size
Viterous inflammation,disc
edema,macular edema are
seen
7.
8. DIAGNOSIS
Fluorescein angiography reveals disc staining,vascular
leakage,and often late CME
Indocyanine green angiography
Optical coherence tomography(OCT)-it may cause vision
loss in BCR
Fundus autofluorescence(FAF) reveals more extensive
hypoautofluorescent lesions
Visual field abnormalities are common with BCR which
includes enlarged blind spot,central or paracentral
scotomas,generalized diminished sensitivity
9. TREATMENT
Corticosteroids are short term mainstay of therapy
They carry their own systemic and local
(glaucoma,cataract) risk
Fluocinolone acetonide
Systemic cyclosporine,azathioprine,low-dose
methotrexate
Anti-vascular endothelial growth factor(anti-VEGF)
are useful in the treatment of CNV associated with
inflammatory chorioretinal disorders
10. EPIDEMIOLOGY AND PATHOGENEIS
Bilateral inflammatory disease
Affecting choriocapillaries,RPE and outer retina in 2nd
and 3rd decades of life
11. OCULAR
MANIFESTATIONS
Sudden painless loss of
vision in one or more
typically both eyes
Transient hearing loss have
been reported
Cerebral vasculitis
No evidence of anterior
uveitis on Ocular
examination
Minimal to no vitreous cell
occur
Flat-to-placoid (plate like)
lesion of variable size
involving posterior pole
12. Lesions do not occur anterior to equator
Lesions of differing ages can be seen associated with
exudative detachments
Lesion tend to clear centrally and become
hypopigmented as they begin to resolve
Optic disc edema has also been noted in APMPPE
13. DIAGNOSIS
Clinical examination,time course and imaging
Placoid fundal lesion highly suggestive of APMPPE
Fluorescein angiography
Indocyanine green shows hypofluorescent lesions in
acute phase of disease
OCT imaging
Areas of hyper-reflectivity have been seen above RPE
in photoreceptor layer
16. PATHOLOGY
Unknown
Vascular insult leading Choroidal ischemia causing
RPE damage
Primary site of inflammation is in the outer retina
which then affects choroid
17. TREATMENT
No treatment is necessary, disease is self-limited
Systemic corticosteroids
Rarely CNV can develop
Anti-VEGF agents are useful in CNVs
18. COURSE AND OUTCOMES
Self-limited course of 2-6 weeks
Vision improves to near normal level during first 2-3
weeks
Complain of difficulty with reading or of scotomas in
the central visual field
Placoid lesion resolve over a period of 2-6 weeks
Permanent disruption of Bruch’s membrane and the
choriocapillaries occurs less frequently in APMPPE
than with serpigious choroidopathy
19. EPIDEMIOLOGY
Also called helicoid peripapillary chorioretinal
degeneration
Affects patients from 2nd to 7th decades
Men and women are affected equally
It is usually bilateral
Affects outer retina,RPE,choriocapillaries and large
choroidal vessels
20. OCULAR
MANIFESTATIONS
Bilateral disease
Symptomatic unilaterally
when the lesions affect the
fovea
Central scotoma with vision
loss
Lesions are geographic grey or
grey yellow begin in
peripapillary region or macula
Unlike APMPPE usually one
eye is active at a time with one
area of focus.
New lesions appear at the
edges of healed scars
Disease has progressive,step-
wise course
21. DIAGNOSIS
Fluorescein angiography demonstrates early
hypofluorescense and late hyperfluorescense of active
lesions
Indocyanine green angiography shows hypofluorescent
active lesions
Choroidal neovascularization shows late leakage and
often arises from borders of old scars
22. Association of Serpiginous choroiditis and tuberculosis
has been suggested
However, treatment of non-TB patients with
antimicrobial agents has made no difference in course
of these patients
23. PATHOLOGY
Loss of RPE with destruction of overlying retina and
lymphocyte
Pathogenesis is unknown
24. TREATMENT
Relapsing and progressive in nature
Therapy is aimed at treating acute episodes and
preventing recurrence that can lead to foveal involvement
Steroids(routes:intravenous,intravitreal,subtenon’s and
via implant)
Aggressive management with corticosteroids used to
treat acute attacks not preventing recurrence
Cyclosporine,azathioprine and other cytotoxic agents
25. Assistance of rheumatologist,oncologist is required due
to its potential systemic side-effects
Anti-VGEF injection
Photodynamic therapy and thermal laser for extra
foveal CNV
Oral acetazolamide for CME
26. COURSE AND OUTCOMES
Foveal destruction may occur
Central visual acuity is lost in 20% or more
Central visual loss
28. OCULAR MANIFESTATIONS
Acute unilateral painless visual loss
Scotoma associated shimmering photopsias, often in
temporal visual field
Numerous,small white spots concentrated in
paramacular area, less prominent beyond vascular
arcades
29. Granular appearance to
fovea is usually present,
fovea does not return to
normal appearance
Vitritis and disc edema
Retinal vascular
sheathing
Circumpapillary
discoloration or white
lesion is the presenting
sign
31. COURSE AND OUTCOMES
Self-limited course
White dots fade and edema resolves within 2-6 weeks
of onset of symptoms
Visual acuity returns to baseline levels
Recurrences are uncommon but have been reported
Visual prognosis is good
Uncommon association of MEWDS with acute macular
neuroretinopathy has been described but unclear
Rare association with AZOOR
32. EPIDEMIOLOGY
Affects young healthy women in 2nd-4th decades of life
Photopsias and dense scotomas
Unilateral or bilateral
Systemic autoimmune disease have been noted in some
patients
33. OCULAR MANIFESTATIONS AND DIAGNOSIS
Fundus finding are usually normal.
Narrow retinal vessels and depigmentation of the
RPE.
Sharp demarcation between normal and abnormal
appearance showing curvilinear appearance.
34. Typically normal.
RPE occur with pigment mottling & window mottling.
A grey white line is seen between normal and
abnormal retina.
OCT irregularity of the IS-OS photoreceptor line in the
areas of retinal involvement.
RPE & Outer retina usually atrophies.
Visual field – superior, temporal and sometimes central
visual field loss.
ERG – severe reduction in a-wave amplitude
35. May show progression and regression with new areas
of involvement.
No specific treatment.
36. Three types of AZOOR exist
1. Type 1 : no other associated WSS.
2. Type 2 : Begins with another WSS
3. Type 3 : No clinical retinal abnormalities are seen but
photoreceptor dysfunction is evidenced on OCT/ERG